Forty Seven, Inc. to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association (EHA)
MENLO PARK, Calif., May 17, 2018 /PRNewswire/ -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that preliminary data from its ongoing Phase 1 clinical trial evaluating 5F9 as a monotherapy for the treatment of relapsed/refractory acute myeloid leukemia will be presented in a poster presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden, June 14-17, 2018.
Initial phase 1 results of the first-in-class anti-CD47 antibody Hu5F9-G4 in relapsed/refractory acute myeloid leukemia patients
Presentation Date & Time:Friday, June 15, 2018 from 5:30 p.m. ? 7:00 p.m. CEST (11:30 a.m. ? 1:00 p.m. ET) Session Title: Acute myeloid leukemia - Clinical Abstract Number: PF232 Location: Poster Area, Stockholmsmässan
About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in five clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...
A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual...
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover...
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the...
Evolent Health, Inc. , a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial...
Canopy Growth Corporation ("Canopy Growth" or the "Company") announced today that in connection with the creation of the non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the "Exchangeable Shares"), on...